secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2022-09-22T23:59:59+00:00
Accession:  0001193125-22-248476
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports BMF-219 preclinical data: HbA1c reduction of 3.5% vs. liraglutide's 1.7% in T2D rat model
--------------------------------------------------------------------------------

- BMF-219 lowered HbA1c by 3.5% vs. liraglutide 1.7% in ZDF rat model; effect maintained through 2-week drug washout.
- BMF-219 restored HOMA-B index to normal range (>201) over 4 weeks, indicating improved beta-cell function.
- BMF-219 treatment resulted in 13% body weight reduction over 4 weeks and lowered total cholesterol and triglycerides.
- Company reaffirms IND submission for BMF-219 in type 2 diabetes in second half of 2022.
- Data presented at EASD Annual Meeting on September 20, 2022 in Stockholm, Sweden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522248476/0001193125-22-248476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522248476/d376137d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-248476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer